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ABSTRACT
Transplant glomerulopathy (TG) is generally accepted to
result from repeated episodes of endothelial activation, injury
and repair, leading to pathological abnormalities of double
contouring or multi-layering of the glomerular basement
membrane. TG is a major sequel of chronic active antibody-
mediated rejection (cABMR), from pre-existing or de novo
anti-HLA antibodies. Hepatitis C infection, thrombotic micro-
angiopathy or other factors may also contribute to TG devel-
opment. TG prevalence is 5–20% in most series, reaching 55%,
in some high-risk cohorts, and is associated with worse allo-
graft outcomes. Despite its prevalence and clinical signiﬁcance,
few well-studied treatment options have been proposed.
Similar to desensitization protocols, plasmapheresis with or
without immunoabsorption, high-dose intravenous immuno-
globulin, rituximab, bortezomib and eculizumab have been
proposed in the treatment of TG due to cABMR individually
or in various combinations. Robust clinical trials are urgently
needed to address this major cause of allograft loss. This
review summarizes the current knowledge of the epidemi-
ology, etiology, pathology, and the preventive and treatment
options for TG secondary to cABMR.
Keywords: chronic active antibody-mediated rejection,
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Transplant glomerulopathy (TG) was traditionally described
as a unique glomerular duplication of the glomerular base-
ment membrane [1]. TG has evolved to be recognized as one
histological feature of chronic antibody-mediated rejection
(cABMR) and is identiﬁed in many cases presenting with
nephrotic-range proteinuria during late allograft dysfunction.
Fifteen years ago, the concept of ‘chronic allograft nephropa-
thy’ induced by calcineurin inhibitor (CNI) nephrotoxicity
was considered the main etiology of death-censored graft loss
based on protocol biopsy studies [2] and was supported by the
observation that long-term graft survival improvements had
not mirrored the marked reduction in acute rejection attribu-
ted to CNI [3]. It became clear in the last decade that cABMR
is the major cause of late allograft loss outside of death with
functioning graft [4].
Peritubular capillary deposition of C4d, as an inactive by-
product of classical complement pathway activation, was re-
cognized as a marker of antibody-mediated graft injury and
subsequently as a predictor of both rejection and long-term
graft outcome [5]. Additionally, this conﬁrmation of alloanti-
body binding was a critical ﬁrst step in understanding and
documenting the inadequacies of traditional immunosuppres-
sion on alloreactive humoral immunity and has resulted in the
introduction of the term of acute and chronic active antibody-
mediated rejection (ABMR) [6–10].
Concurrent improvements in HLA antibody detection
methods (solid-phase assays in particular single antigen bead
platforms—SAB) have permitted extensive investigation into
the clinical signiﬁcance of donor-speciﬁc HLA antibodies
(DSA). Recent analyses have conﬁrmed the strong association
of DSA and antibody-mediated graft injury with death-cen-
sored graft loss [11–13]. In combination with increasingly ac-
curate and detailed histopathologic evaluation of renal
allograft biopsies, TG is now clearly classiﬁed as one of the
ﬁnal pathways of chronic active antibody-mediated rejection
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(cABMR) with incorporation into the Banff classiﬁcation
[13–17].
This review will summarize current knowledge in epidemi-
ology, etiology and pathology of TG secondary to cABMR and
detail prevention and treatment options. Other causes, such as
hepatitis C virus (HCV) infection and thrombotic microangio-
pathy, are not within the scope of in this review, but they have
been recently discussed elsewhere [18].
EPIDEMIOLOGY OF TG SECONDARY
TO cABMR
The prevalence of TG secondary to cABMR is poorly de-
scribed in the literature. Analysis of one Italian center’s 666
graft biopsies data (collected between 1983 and 2000) demon-
strated TG in 5.6% [19]. A higher incidence (12%) was repor-
ted from the Mayo Clinic group during 4.5 years of follow-up
[20]. The same group reported in a 582 patient cohort, a
cumulative incidence of 20% at 5 years [15] in patients with
negative pre-transplant T-cell complement-dependent cytotox-
icity cross-match (CDCXM) compared with 54.5% in a differ-
ent desensitized positive CDCXM cohort [21]. Development of
TG is strongly associated with both pre-existing or de novo DSA
[22–24]. With improved sensitivity, negative ﬂow cytometry
cross-match (FCXM) patients have improved outcomes com-
pared with FCXM-positive recipients [25].
TG independently impacts on graft survival; however, other
factors (presence of proteinuria, C4d positivity, class type of
DSA) can modify outcomes. TG patients with signiﬁcant pro-
teinuria (>2.5 g/day) reported much worse graft survival out-
comes (92 versus 33%, P < 0.001) compared with those with
less proteinuria [19]. In a Mayo Clinic trial of 102 CDCXM
positive subjects with 204 age- and sex-matched negative
cross-match (XM) counterparts, graft survival was signiﬁcant-
ly worse in patients with Class II DSA (alone or with Class I)
in comparison to Class I DSA alone (63 versus 85%, P = 0.05).
Those without Class II DSA had similar survival to negative
XM recipients (85 versus 88%, P = 0.64) [21]. Buob et al. com-
pared 20 TG patients without C4d positivity or morphologic
evidence of rejection with 44 recipients without TG or rejec-
tion histopathology. At 3 years, renal function, acute rejection
and development of HLA antibodies were not signiﬁcantly dif-
ferent between the two groups [26].
PATHOLOGY OF TG SECONDARY TO cABMR
According to the Banff 2013 classiﬁcation, the biopsy diagno-
sis of cABMR should meet three criteria [13]:
(1) Presence of donor-speciﬁc alloantibodies,
(2) Demonstration of alloantibody interaction with vascular
endothelium: complement 4d-positivity in peritubular
capillaries and/or at least moderate microvascular in-
ﬂammation (MVI) and/or increased gene expression of
endothelial activation and injury transcripts (ENDATs),
(3) Morphologic signs of alloantibody-induced chronic vas-
cular injury: TG and/or severe peritubular capillary base-
ment membrane multi-layering and/or new onset
arterial intimal ﬁbrosis.
One of the most speciﬁc histologic phenotypes of cABMR
is TG (Figure 1) [18]. Pathogenetically, persisting or de novo
anti-endothelial DSA, particularly to HLA antigen Class II al-
loantigens [15, 27], activate and cause sublytic injury to the
glomerular capillary endothelial cells [28]. The subsequent
repair process produces a new basement membrane layer. Re-
peated episodes of endothelial activation, injury and repair
result in the deposition of several basement membrane layers
involving the entire capillary circumference. The new layer(s)
are recognized as double contouring or multi-layering of the
glomerular basement membranes (GBMs) on tissue sections
stained with periodic acid-Schiff or methenamine silver stain
that highlight the GBM. A similar pathological multi-layering
feature can be seen in the peritubular capillary basement
membrane. Since the peritubular capillary basement mem-
branes are much thinner than the GBMs, the gold standard in
the assessment of peritubular capillary lamination is the ultra-
structural evaluation of the peritubular capillary basement
membranes [29].
Overt TG is now characterized histologically by GBM dupli-
cation in ≥1 of the capillary loops (as opposed to the previous
criterion of >10% of capillary loops), mesangial expansion with
or without mesangial hypercellularity and mesangial cell inter-
position; glomerulitis can accompany these lesions [13]. The
immunostaining for C4d discloses diffuse or focal linear C4d
along peritubular capillaries (C4d-positive, antibody-mediated
rejection) or the C4d staining is negative (C4d-negative, anti-
body-mediated rejection). Thus, glomerulitis and/or C4d de-
position and the presence of DSA indicate the ongoing active
nature of the rejection process. The immunostaining for im-
munoglobulin G (IgG), IgA and C1q is negative; IgM and C3
can be mildly or moderately positive in the mesangium and
along the capillary loops. Electron microscopy reveals multi-
layering of GBMs in several loops with or without signs of
endothelial activation. In some analyses, DSA and peritubular
C4d were absent, indicating such an antibody-mediated rejec-
tion independent form, but these cases may also represent a
temporary inactive cABMR period based on the similar
outcome results with the full cABMR cohort [30]. Overt TG is
regularly accompanied by chronic damage to the allograft par-
enchyma: ﬁbrous intimal thickening of arteries, arteriolar hya-
linosis, segmental and/or global glomerulosclerosis, interstitial
ﬁbrosis, tubular atrophy, circumferential multi-layering of peri-
tubular capillary basement membranes and sometimes loss of
peritubular capillaries. Signiﬁcant proteinuria, hypertension
and slowly worsening graft function are observed clinically.
The differential diagnosis of TG includes diseases that lead
to GBM duplication: membranoproliferative glomeruloneph-
ritis, lupus glomerulonephritis, HCV infection-related glomer-
ulonephritis and smoldering thrombotic microangiopathy.
The diagnosis is usually straightforward if immunoﬂuorescent
and ultrastructural examination of the renal biopsy sample is
performed. Hemolytic-uremic syndrome or anti-phospholipid,
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antibody-induced chronic thrombotic microangiopathy can,
however, cause difﬁculties in the differentiation from TG if
the C4d staining is negative. Based on previous data and one
series of indication biopsies of a cyclosporine–azathioprine–
corticosteroid-treated renal transplant cohort, an overlapping
pathway of cABMR, thrombotic microangiopathy and HCV
infection-associated glomerulopathy, was hypothesized [15, 31].
Chronic ABMR lesions are irreversible and worsen with
time and, therefore, the early biopsy diagnosis of TG would fa-
cilitate the development of treatment options. The features of
early TG have been observed in protocol biopsies and include
glomerulitis and no double contours (Banff cg score 0). The
C4d immunostaining reveals either diffuse or focal linear C4d
deposition along peritubular capillaries or is negative; the
staining for immunoglobulins and early complement compo-
nents are negative. The ultrastructural investigation demon-
strates signs of endothelial activation, i.e. hypertrophy/swelling
of the cell bodies, disappearance of fenestrations and widening
of the subendothelial space [32–35]. A new, continuous
basement membrane layer along the entire capillary circum-
ference can be observed in a few loops (Banff cg score 1a).
Focal ﬁbrin and platelet microthrombi are additional ultra-
structural signs of active injury. It should be emphasized that
the ultrastructural alterations per se are not speciﬁc for early
TG, and all ﬁndings observed by light microscopy, immuno-
histochemistry and electron microscopy, together with the
presence of DSA point to early cABMR. The lesions of early
TG are usually associated with mild proteinuria and/or unex-
plained mild deterioration in allograft function [15].
The alloreactive immune response of the host is a continu-
ous process, underlying the nature of the pathological ﬁndings.
The rigorous, binary distinction between ‘acute’ or ‘chronic’
antibody-mediated rejection is necessary for a descriptive diag-
nosis, but over time, the full spectrum of humoral immunity
may result in tissue injury and repair in the biopsy specimens.
TG indicates a late and generally non-reversible manifestation
of this process and is viewed as an ‘end-product’ of the anti-
body-mediated pathophysiological process.
F IGURE 1 : Early transplant glomerulopathy was diagnosed using electron microscopy in a 6-month protocol biopsy. (A) Light microscopy re-
vealed leukocyte accumulation (arrowheads) in the glomerular and peritubular capillaries (glomerulitis and peritubular capillaritis, respectively);
double contoured glomerular capillary walls were not observed (hematoxylin–eosin stain; original magniﬁcation, ×400). (B) Immunoﬂuores-
cence demonstrated C4d positivity in peritubular capillaries (C4d stain; frozen section, original magniﬁcation, ×200). (C) Electron microscopy
of glomerular capillaries revealed subendothelial widening, focal loss of endothelial cell fenestrations and the duplication of glomerular basement
membrane along the entire capillary circumference (arrowhead) in three loops (uranyl acetate and lead citrate stain, original magniﬁcation,
×7000). Several peritubular capillaries displayed 3–4 circumferential basement membrane layers. Serology conﬁrmed the presence of de novo
donor-speciﬁc alloantibodies. (D) Well-developed transplant glomerulopathy is characterized light microscopically by widespread double con-
tours of capillary loops (arrowheads). Asterisks indicate segmental sclerosis (methenamine silver, original magniﬁcation, ×400).
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PATHOPHYSIOLOGY OF TG SECONDARY
TO cABMR
Recurrent alloantibody-mediated (HLA antigen or non-HLA
antigen) endothelial injury is the major factor of development
of TG secondary to cABMR, and several distinct patterns of
pathophysiological process have emerged even though our
current knowledge on the intra-graft events is particular. Al-
loantibody binding to endothelial surface antigens may induce
different intracellular signaling leading to endothelial activation,
recruitment of natural killer (NK) cells, monocytes and lesser
T-lymphocytes and neutrophil granulocytes. Recent studies
have shown that alloantibody-dependent cellular cytotoxicity is
triggered by interaction of Fc-γ RIII on NK cells turning to ex-
pression to T-bet and IFN-γ production and increased levels of
NK transcripts might have been detected during cABMR [36,
37]. Related to MVI, there is evidence that ENDATs and DSA-
dependent transcripts are indicators of ongoing ABMR and
their identiﬁcation in C4d-negative renal biopsy specimens have
established signiﬁcance [38]. The presence of complement acti-
vation and C4d deposition is more characteristic to acute
ABMR (aABMR) but in the case of complement-activating
IgG1 and IgG3 DSAs, a ﬂuctuating C4d status may accompany
the process of cABMR and subsequent graft loss. Urine and/or
plasma mRNAs, chemokines and other potential biomarkers to
identify either TCMR or ABMR are under current investigations
and have been recently discussed elsewhere [39, 40].
Growing evidence has been emerged in the last years on the
effect of non-HLA antibodies on short- and long-term
outcome. In the database of Collaborative Transplant Study,
the pre-transplant presence of antibodies targeted to major
histocompatibility complex (MHC) Class I-related chain A
(MICA) antigens was associated with poorer outcome even in
the case of good HLA matching [41]. However, it is important
to note that in this cohort anti-HLA DSA was poorly charac-
terized and most cases where MICA is positive also have HLA
antibodies as well [41]. Additionally, angiotensin II receptor
type 1 activating autoantibody (AT1R Ab) has been conﬁrmed
behind graft loss [42–45]. Again, it is important to note that
majority of patients did not have anti-HLA antibody tested on
the same sera with AT1R Ab, which is not the same as not
having anti-HLA antibody. A better observation is that in
some patients the impact of anti-HLA antibody and AT1R Ab
was additive [46]. De novo anti-endothelial cell antibodies
(EACAs) rather than pre-existing EACAs were also independ-
ently associated with glomerulitis and peritubular capillaritis
[47]. Although their utility has yet to be demonstrated in a
broader clinical setting, these early investigations are clearly
supportive of a broader consideration of agents of antibody-
mediated graft injury beyond HLA DSA-associated mechanisms.
CLINICAL AND IMMUNOLOGICAL RISK
FACTORS OF TG SECONDARY TO cABMR
The evolution of the Banff classiﬁcation [13] makes it difﬁcult
to compare different immunosuppressive protocol impact on
the natural history of TG or cABMR. In the cyclosporine era
and before the introduction of mycophenolic acid, TG had
been identiﬁed in 5.6% of cases of for-cause biopsies in a large
Italian patient cohort with 10-year graft survival of 48 com-
pared with 88% in controls [19]. With the introduction of ta-
crolimus, a case–control study was performed to compare the
results of protocol graft biopsies in tacrolimus- versus cyclo-
sporine-treated recipients, otherwise receiving corticosteroids
and mycophenolic acid, and found signiﬁcantly lower Banff cg
score for tacrolimus-treated patients [48]. Suboptimal drug ex-
posure is now widely accepted in the etiology of dnDSA ap-
pearance, aABMR late chronic AMR and subsequent graft
loss. Non-adherence of recipients is one of the major causes of
ineffective immunosuppression and late graft loss as well as
physician-recommended modiﬁcation in the immunosuppres-
sion therapy [12, 49]. A recent analysis showed a reduction in
immunosuppression leading to late ABMR in 17% of patients
[50]. Furthermore, CNI minimization or other withdrawal
strategies might further increase the risk of dnDSA develop-
ment and late acute or chronic ABMR [51, 52].
Pre-transplant/pre-existing high-titer, donor-speciﬁc IgG
anti-HLA antibodies detected by CDCXM and resulting in hy-
peracute rejection were considered a contraindication to trans-
plant [53]. FCXM and SAB detection of low-titer DSA,
undetectable by CDCXM, have improved identiﬁcation of sen-
sitized kidney transplant recipients [54]. Mohan et al. per-
formed a systematic review and meta-analysis of rejection rates
and graft outcomes for renal transplant recipients with pre-
formed low-titer DSA, deﬁned by positive SAB but negative
CDCXM and FCXM. SAB identiﬁed DSA with negative
CDCXM, nearly doubles the risk for AMR and increases risk
for graft failure by 76% [55]. Moreover, increased risk was also
found in the case of DSA-positive/FCXM-negative recipients
[56]. These results are not universal and many patients with
only SAB assay-positive DSA have achieved good long-term
renal graft function [57]. Identiﬁcation of antibody strength in
studies using mean ﬂuorescence intensity (MFI) in the SAB
assay is common, but this is a semi-quantitative test [58, 59].
The FCXM assay is similarly not standardized [60]. Studies re-
porting MFI and rejection outcomes must be interpreted in
this context. A consensus conference guidelines on HLA and
non-HLA antibodies in transplantation recommends that in
renal transplantation, if DSA is present but the CDCXM
against donor T and B cells is negative, this should be regarded
as an increased risk but not necessarily a contraindication to
transplantation, especially after elimination of DSA by desen-
sitization [57]. Persistence of pre-existing Class I DSA post-
transplant is highly correlated to the emergence of early acute
ABMR and should be recognized as a risk factor of TG devel-
opment [22, 61].
Late aABMR (which frequently has histopathologic features
of acuity and chronicity) and cABMR/TG are strongly related
to the de novo appearance of donor-speciﬁc IgG HLA anti-
bodies (dnDSA). During long-term follow-up, 15–29% of reci-
pients develop de novo, predominantly Class II DSA frequently
to HLA-DQ antigens [22–24]. In a study of 315 kidney trans-
plant recipients without pre-transplant DSA, 15% of the cohort
has developed dnDSA, mainly secondary to non-adherence,
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during a 6.3-year mean follow-up time, and 61% of them have
shown signs of acute or indolent ABMR on indication or sur-
veillance biopsy. The median 10-year graft survival for the
dnDSA patient group was signiﬁcantly, 40%, lower than non-
DSA patient group [49]. In a recent study of 245 kidney trans-
plant recipients without pre-existing DSA at 12 months, 8.2% of
them had dnDSA and those who had an MFI value of 3000 or
greater had almost 11-fold higher risk for aABMR [hazard ratio
(HR): 10.6, 95% conﬁdence interval (CI): 2.27–49.5], but indi-
cating the late onset in non-immunized recipients, TG has not
occurred in any cases at 12-month surveillance biopsies [62].
The harmful effect of dnDSA is not proven for all cases, but the
presence of complement-binding IgG1 and IgG3 dnDSA gener-
ally negatively impacts long-term outcome and may be asso-
ciated with 30% lower 5-year graft survival [63]. Analyzing a
large kidney transplant population, from 316 DSA-positive pa-
tients, 77 patients had C1q-binding DSA. Additionally, the
presence of C1q-binding, post-transplant DSA was associated
with the increased risk of graft loss (HR: 4.78, 95% CI: 2.69–
8.49) after adjustment for several immunological, histological
and clinical factors [64].
The development of desensitization protocols in the last 15
years has permitted a greater number of kidney transplants
across DSA, positive cross-match barriers and ABO incom-
patibility offering the possibility of successful transplantation
to highly sensitized recipients otherwise unlikely to receive a
kidney graft on the waiting list. Even if achieving a pre-trans-
plant negative CDCXM, these recipients remain immuno-
logically high risk with high incidence of ABMR, due to
memory responses that cannot be completely abrogated with
desensitization. In the pilot trial of the Mayo Clinic comparing
the results of 12-month post-transplant protocol biopsies, TG
was diagnosed in 22% of the previously positive cross-match
(+XM) group versus 8% of conventional patients [65]. In
further analysis, the strength of pre-transplant DSA was
loosely correlated with the increased risk of early aABMR but
not with TG, beyond the presence of DSA alone [66]. Five-
year outcomes of this +XM patient cohort have shown inferior
death-censored graft survival compared with conventional
renal transplant recipients (70.7 versus 88%; P < 0.01) and
consistent with this association, TG was present in 54.5% of
surviving grafts and equally common in Class I and Class II
DSA subgroup [21]. In the +XM renal transplant program
of Johns Hopkins University, the occurrence of TG was 25% at
1-year protocol biopsy histology and resulted in worse graft
survival compared with control XM-negative patients (66.7
versus 96.6%; P < 0.001) during a 42-month median follow-up
[67]. During the entire study comprising 129 +XM recipients
with 745 graft biopsies, TG developed in 47% of patients as
early as 3 months. In recipients having glomerulitis in the spe-
cimens of ﬁrst 3 months, TG developed in 61% within an
average of 15 months [68]. Despite a high proportion of pa-
tients having antibody-mediated renal graft injury, live donor
kidney transplantation and desensitization protocols have pro-
vided an increased survival beneﬁt compared with sensitized
patients on maintenance dialysis [69].
The outcome results of ABO-incompatible renal trans-
plantation after the 15th postoperative day are similar to ABO
compatible ones [65]. Later, the rates of chronic antibody-
mediated graft injury and the occurrence of TG were similar in
ABO incompatible renal grafts and ABO compatible grafts
[65]. The special histological feature of ABO incompatible
grafts is the very common C4d deposition at peritubular capil-
laries without an inﬂammatory response or pathological
injury [70, 71]. The phenomenon of accommodation is under
extensive investigations for understanding its potential thera-
peutic potential.
PREVENTION OF TG SECONDARY TO cABMR
The most important primary prevention of TG secondary to
cABMR is to perform transplantation without pre-existing
DSA. Compelling evidence exists to show that pre-existing
DSA has a major impact on TG and long-term graft survival
[27]. An other primary prevention method is to avoid trans-
plantation with HLA mismatches, especially Class II HLA
mismatches, which has been shown as strong predictor of the
presence of DSA [72]. Moreover, Sapir-Pichhadze [73] ele-
gantly demonstrated a Class II EPLET mismatch as an inde-
pendent predictor of TG in a nested case–control study.
As both pre-transplant and de novo donor-speciﬁc IgG
anti-HLA antibodies play the most signiﬁcant role in the de-
velopment of cABMR/TG, any secondary prevention, which
can eliminate these antibodies, can reduce the probability of
development of TG. Three major desensitization protocols in
use today are plasmapheresis (PLEX) with or without immu-
noabsorption (IA), high-dose intravenous immunoglobulin
(IVIG) and PLEX combined with low-dose IVIG and rituxi-
mab [74]. In the mid-90s, Alarabi et al. treated 23 sensitized
(PRA>50%) waitlisted patients with 12 sessions of PLEX and
cyclophosphamide and prednisolone. Although a majority of
patients’ PRA decreased signiﬁcantly, most of these patients
lost their graft secondary to rejection [75]. Later, Gloor et al.
introduced a complex protocol that includes PLEX (4–5 ses-
sions), low-dose IVIG, rituximab and splenectomy combined
with thymoglobulin induction and tacrolimus/MMF/prednis-
olone maintenance treatment. They reported excellent graft
and patient survival with very low rejection rate (14% clinical
and 29% subclinical) [76]. Similar to PLEX, the more expen-
sive IA (using protein A column) can also effectively reduce
the DSAs; however, this effect is mostly temporary [77].
Almost all desensitization protocols include a high dose (2
g/kg) or low dose (100 mg/kg)—always linked with PLEX–
IVIG treatment. High-dose IVIG was able to reduce PRA and
DSAs in most of the studies [74]; however, IVIG failed to
lower the strength of DSAs in at least two previous trials [78,
79]. In the last decade, rituximab (1 g twice), an anti-CD20
monoclonal antibody, was also given with IVIG as desensitiza-
tion treatment. Vo et al. [80] reported a signiﬁcant decrease in
PRA (from 77 ± 19 to 44 ± 30%) and excellent patient and
graft survival in 16 highly sensitized patients. After this land-
mark trial, PLEX with IVIG and rituximab were the backbones
of most of these protocols and experienced excellent (0–55%)
rate of ABMR and patients’ and graft survival [74].
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Recently, the protocols described above have been augmen-
ted with new therapeutic agents. Two of these, in wide use, are
bortezomib, a proteasome inhibitor that leads to apoptosis of
plasma cells, and eculizumab, a humanized antibody speciﬁc
for the C5 component of complement that prevents formation
of the membrane attack complex (MAC) [74]. The efﬁcacy
and side effects of interventions for the prevention/treatment
of TG secondary to cABMR are summarized in Table 1.
TREATMENT OF TG SECONDARY TO cABMR
The treatment of aABMR does not differ substantially from
desensitization protocols. However, all treatments are sup-
posed to be given early before chronic changes have already
been developed. The combinations of IVIG, PLEX/IA, rituxi-
mab and new agent, bortezomib, are widely accepted in post-
transplant care with the additional administration of eculizu-
mab in some studies [81–83]. Recent reviews summarize the
development in this ﬁeld in contrary to the very scarce case
series-based literature results of the identical protocols used in
the setting of cABMR [84, 85]. In a prospective pediatric study
of aABMR and cABMR, four weekly doses of IVIG (1.0 g/kg
body weight at each session) followed by a single dose of ritux-
imab decreased the progressive loss or stabilized transplant
kidney function during a 24-month observation period in 5 of
11 patients with TG. Only 9 of 20 patients had a follow-up
biopsy without detailed data regarding cABMR histological
outcome [86]. In a recent study, high-dose IVIG alone has
been proven to be unfavorable for the treatment of cABMR.
Nine of 20 treated patients had a follow-up biopsy and only 4
had no histological progression [87]. Based on the favorable
results of the use of bortezomib in late aABMR, a patient
cohort comprising nine patients with cABMR, and seven of
them having TG, was treated effectively with PLEX, low-dose
IVIG, rituximab and bortezomib combination, and 22 of
23 patients underwent follow-up biopsy. Lack of a histologic
response was associated with older patients [odds ratio (OR) =
3.17], the presence of cytotoxic DSA at the time of diagnosis
(OR = 200) and severe chronic vasculopathy (cv > 2) on index
biopsy (OR = 50) [50]. However, such an improvement could
not be achieved in other series [88, 89]. The advantage of add-
ition of eculizumab to these protocols remains to be elucidated
further [90]. Multicenter clinical trials of bortezomib, rituxi-
mab, eculizumab and cyclophosphamide for the treatment of
cABMR are ongoing or recruiting patients [18, 22, 91, 92].
In the current era of immunosuppressive drugs, splenec-
tomy takes back seat in the treatment options of cABMR;
nevertheless, its usefulness as a rescue therapy has been pub-
lished [93, 94] and shown to be more efﬁcient in combination
with eculizumab in the clinical setting of +XM transplantation
[95]. Out of the 24 patients, there was more chronic glomeru-
lopathy in the splenectomy-alone and eculizumab-alone
groups at 1 year, whereas splenectomy + eculizumab patients
(n = 5) had almost no TG. Splenectomy is likely to remain
controversial in the setting of ﬁnancially strongly supported
transplant programs in developed countries but may provide a
solution for transplant programs having more unassertive ﬁ-
nancial circumstances.
Much effort is being made to develop and investigate new
therapeutic options for the prevention and treatment of acute
and chronic ABMR. Newer maintenance immunotherapies
with the co-stimulatory pathway blocking belatacept may
provide additional inhibition of donor-speciﬁc B cells, and po-
tential beneﬁt to prevent cABMR is supported by the 3- and 5-
year outcome results of belatacept studies [96, 97]. They are
currently investigating B-cell-depleting therapies in systemic
lupus erythematosus (SLE) as anti-CD20 antibody ocrelizu-
mab and anti-CD22 antibody epratuzumab may be an inter-
esting area of research in renal transplantation [98]. The
controlling of anti-apoptotic survival factors critical for the
maturation of the B-cell lineage is also a promising target for
therapeutic interventions. The humanized monoclonal anti-
BlyS antibody belimumab is under current investigation in
Phase III SLE trial, and recruitment of patients into a Phase-II
study of both APRIL and BlyS ligand inhibiting immuno-
globulin fusion protein atacicept is currently ongoing [99].
Understanding the pathophysiological process leading to
TG potentially explains its therapeutic resistance. Whereas the
treatment options are very scarce, awareness of patient non-
adherence and the avoidance of suboptimal maintenance
immunosuppression is currently the best way to prevent the
Table 1. Efﬁcacy and side effects of interventions for the prevention or treatment of antibody-mediated graft injury
Desensitization
protocols
Acute ABMR
treatment
Chronic ABMR
treatment
Potential adverse events Cost
1. PLEX + + ± Hypotension, bleeding, hypovolemia +
2. IVIG + + ± Allergy, headache, myalgia, fever +
3. Rituximab (Rx) ++ ++ + ? Infections, neutropenia, infusion reactions ++
4. Bortezomib (Bx) ND +++ + ? Myelosuppression, neuropathy GI toxicity ++
5. Eculizumab (Ex) NA ++ + ? Meningococcal infection, hypertension +++
6. Splenectomy (Sx) ++ ++ + ? Infections, thrombocytosis +
7. PLEX + IVIG ++ ++ ± Additive Additive
8. IVIG + Rx ++ ++ +
9. PLEX + IVIG + Rx +++ +++ NA
10. PLEX + IVIG + Sx +++ +++ + ?
11. PLEX + IVIG + Rx + Bx ND +++ +
12. PLEX + IVIG + Rx + Ex NA ++++ ND
ND, no data; NA, not applicable; ±, occasional; ?, few data, not exactly known.
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occurrence of cABMR and TG to provide good long-term
transplanted kidney survival results.
EPILOGUE
TG secondary to cABMR is one of the most annoying pro-
blems that transplant nephrologists have to face in 2014.
Despite this fact, we have succeeded in better understanding of
pathophysiology of these diseases; the effective and safe treat-
ment is still unknown. In the near future, the transplant com-
munity needs to perform well-designed clinical trials in a well-
deﬁned recipient population.
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ABSTRACT
Nephrosclerosis is an umbrella term deﬁning changes in all
compartments of the kidney, changes caused by hypertension and
by ageing. Among other lesions, arteriolosclerosis and arteriolo-
hyalinosis play a major role in inducing glomerular ischaemic
shrinking and sclerosis along with glomerulomegaly and focal-
segmental glomerulosclerosis (FSGS). These lesions are accom-
panied by tubulointerstitial inﬂammation and ﬁbrosis that predict
the decline of renal function. Nephrosclerosis is a major cause of
renal insufﬁciency in blacks of African descent with a severe, early
form of renovasculopathy and a rapid course to renal failure with
predominant lesions of FSGS. It seems that in blacks, separate
genetic factors independently lead to vascular lesions and to
hypertension with a different time-scale of their onset and of their
progression, nephroangiosclerosis preceding the onset of hyper-
tension. Conversely, true and histologically identiﬁed nephro-
sclerosis in white Europeans rarely leads to end-stage renal disease
in the absence of malignant hypertension. Various animal models
demonstrate that renal vascular lesions may exist in the absence of
hypertension. These experiments also point to a major role of
angiotensin II and of a number of independent and overlapping
cellular and molecular pathways in a cascade of inﬂammatory
events that end in renal ﬁbrosis. Two pathophysiologic mechan-
isms are at work in inducing glomerular lesions and tubulointer-
stitial ﬁbrosis: a loss of autoregulation of the renal blood ﬂow
caused by an arteriolohyalinosis of the glomerular afferent arteri-
ole and ischaemia that fosters the generation of hypoxia indu-
cible-ﬁbrosing factors. Not all antihypertensive drugs equally
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